- On January 27, Premier Li Qiang signed a decree announcing the revised Implementation Regulations of the Drug Administration Law, effective May 15, 2026.
- The updated regulations, marking the first comprehensive revision in over 20 years, enhance drug research, approval processes, and production management, while emphasizing innovation and public access to safe medications.
- Key changes include support for pediatric and rare disease drug exclusivity periods, stringent online sales regulations, and the introduction of a segmented production system to boost production efficiency.
